Searched for
EXTENSION FOR DRUG COMPANIES
Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...- Cipla appoints health chief Shivam Puri to lead One India businessCipla has appointed Shivam Puri as the new Chief Executive Officer for its One India Business. This significant leadership change will take...
- Florida sues TikTok, claiming it violates state child safety lawThe lawsuit seeks a court order directing the platform, which is owned by ByteDance, to make changes to bring it into compliance with the l...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Over 60% of pharma MSMEs yet to comply with updated manufacturing normsPharma industry officials say the revised Schedule M regulations could require Rs 10-15 crore per facility in upgrades, while talent shorta...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- AI-Powered drug discovery could transform treatment development for Alzheimer’s, Parkinson’s and other brain disorders.Researchers are increasingly using AI to accelerate the search for treatments for neurological conditions such as Alzheimer’s, Parkinson’s,...
- Wockhardt gets CDSCO nod for Zaynich antibioticWockhardt Ltd has secured approval from the CDSCO for its new antibiotic, Zaynich. This drug is developed in India and will be used to trea...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Eli Lilly’s obesity drug shows up to 30% weight loss in trialEli Lilly's new obesity drug retatrutide shows remarkable results. In a major trial, patients lost up to 30% of their body weight. This onc...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- Sun Pharma-Organon deal: How a $12-billion merger will reshape India's pharma landscapeSun Pharma is set to nearly double its revenue to $12 billion with the acquisition of Organon, creating a global pharmaceutical giant. The ...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Ministry in talks with states to give some drug cos more time for good manufacturing practices complianceThe Union Health Ministry is in talks with states about extending the deadline for pharmaceutical companies to meet new manufacturing quali...
- Pharma companies must file compliance strategyDrugmakers must complete a gap analysis and submit their compliance strategy to extend Schedule M implementation. Small and medium manufact...
- Government extends deadline for small drug companies to comply with revised schedule M standardsThe government is expected to extend the deadline for small drug companies to comply with the revised Schedule M standards until December 3...
- Pharma companies may get time till December to comply with schedule M normsThe govt may extend the deadline for drug manufacturers to comply with revised Schedule M standards until December 2025. A final notificati...
- Breast cancer biosimilar approval delayed as US FDA reviews additional information by Biocon, MylanBiocon and Mylan have together developed the trastuzumab biosimilar, which is a copy of a complex biologic drug developed by Swiss biotech ...
- Companies oppose extension of new drug validity periodAs per current provisions, an application for a ‘new drug’ is approved only by the central drug regulatory agency for four years.
- Pharma pops brand-extension pillThe strategy of brand extensions, one of the biggest branding tools in the FMCG industry, is now finding application in the Indian pharma s...
Load More
